{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gout/prescribing-information/colchicine/","result":{"pageContext":{"chapter":{"id":"cadf7df3-5301-560b-a8ff-e85cfee9ba7c","slug":"colchicine","fullItemName":"Colchicine","depth":2,"htmlHeader":"<!-- begin field 0798f2b4-1ec1-4849-b22f-a8b058f4fa12 --><h2>Colchicine</h2><!-- end field 0798f2b4-1ec1-4849-b22f-a8b058f4fa12 -->","summary":"","htmlStringContent":"<!-- begin item 5cb325c9-82e4-41d6-b616-a89c231801aa --><!-- end item 5cb325c9-82e4-41d6-b616-a89c231801aa -->","topic":{"id":"7ec7842e-cb8a-5712-bb55-65480a391cb5","topicId":"b578fac4-ab4b-4d7b-9df9-2136b4d90e75","topicName":"Gout","slug":"gout","lastRevised":"Last revised in February 2018","chapters":[{"id":"2e71494e-f9a3-5368-8903-3d2121329748","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738bb44e-1a50-5bc5-8df4-83ac66475493","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69338c48-0d43-5ae0-9591-5ef289880366","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0f7680ff-9a88-520a-b2b5-1ff130dfa69b","slug":"changes","fullItemName":"Changes"},{"id":"ae66c6f1-78f9-5532-b310-9d6957882c0c","slug":"update","fullItemName":"Update"}]},{"id":"5de6e4cf-e0c8-56e2-a357-3d063b324cd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"86664a1d-e3e5-58c9-957b-56affa17f103","slug":"goals","fullItemName":"Goals"},{"id":"39593d8e-f904-5b99-80e9-e619caf1ec37","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca59f248-a0b2-5f6c-bfcf-2333dc94f1d9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"57ca55f4-826e-5832-85a7-dd89f3486be2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"621c09b7-b5e8-593b-aeb2-fc4a86b884c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b39fbed2-7c0d-5440-a769-bab311a7b4d2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"362edeaf-2f90-506d-b203-f5dbbbfb5835","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a8de4056-6ec0-59ff-911b-561bf7fdb32d","slug":"definition","fullItemName":"Definition"},{"id":"45a8241d-2a2d-5a48-a6d6-2b5ebe02ec27","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"92d229bf-8656-5cfa-aecc-9c069389300f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"79d3b1c2-8d49-55be-99af-41b37c84d582","slug":"complications","fullItemName":"Complications"},{"id":"27dd91cd-92bb-5c2d-8fe8-a184bffce6e7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ca0e383b-327b-58c2-adb4-6c5081b6fd8e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ddea0193-0c14-53db-8e1e-2e71f514988e","slug":"assessment","fullItemName":"Assessment"},{"id":"5a86623b-b32c-5e12-b9fe-b1b5a1f7e58f","slug":"investigations","fullItemName":"Investigations"},{"id":"42a5d4a2-b908-5027-8fb8-f5f336db4c7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5a915955-8e0e-54ae-a1cc-f5875d84d2a2","fullItemName":"Management","slug":"management","subChapters":[{"id":"8a8b4d2a-4efb-5bef-9780-70dc540d41bd","slug":"acute-gout","fullItemName":"Scenario: Acute gout"},{"id":"98793041-11dd-5159-a376-82f5440ee713","slug":"preventing-gout","fullItemName":"Scenario: Preventing gout"}]},{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e7cfef3f-4ab1-5d17-8300-30e91a70eb96","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"cadf7df3-5301-560b-a8ff-e85cfee9ba7c","slug":"colchicine","fullItemName":"Colchicine"},{"id":"60f4beab-f8fc-50e5-8ed9-5073dd8533ec","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"2d2fee49-9ad0-5f0a-9ef1-f253794ed2c7","slug":"allopurinol","fullItemName":"Allopurinol"},{"id":"9830ccbd-f551-5585-a69a-4674759f70cd","slug":"febuxostat","fullItemName":"Febuxostat"},{"id":"ff3edf82-1b21-591c-a8a5-a3b40e7386a5","slug":"paracetamol","fullItemName":"Paracetamol"}]},{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"71a86333-9110-5847-a2c2-eabf7903c269","slug":"application-of-an-ice-pack","fullItemName":"Application of an ice pack"},{"id":"25688946-80c0-52ab-a32d-99ccab4d738c","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2921e0f0-467f-5231-87d0-9fed766653ee","slug":"oral-colchicine","fullItemName":"Oral colchicine"},{"id":"09bbf9d4-fe62-5ae1-bc49-f2fede12f711","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"409d2bc0-16d2-5104-8857-eeb5db2a1ecc","slug":"dietary-measures","fullItemName":"Dietary measures"},{"id":"08526f72-ca5a-50db-94b6-3380365360fd","slug":"colchicine-to-prevent-recurrent-gout","fullItemName":"Colchicine to prevent recurrent gout"},{"id":"a53517a7-6d7e-5d2f-886d-e2a3f1bc27b1","slug":"urate-lowering-drugs-in-prevention","fullItemName":"Urate-lowering drugs in prevention"}]},{"id":"f83d98a9-6ce1-50d4-92ad-dd354662a444","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"568c43a6-b0d8-546e-84d2-45781ce305cc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5b7cac11-c21d-59fc-83d9-bf16d0d3ab0b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0e4d0013-b7bc-5179-ac55-8104dec2762c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d75afbe0-7c3d-504e-b369-e56eac297bad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"45249d1d-8c92-5402-b4f3-108a8a39d94f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"44f1a411-2cf4-55e8-b5e8-266cd568655e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"db0e8805-fa41-5946-9520-22ac54f1f85f","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 81460889-3191-4450-aee3-bceafc3e621a --><h3>What dosing regimen of colchicine should I use?</h3><!-- end field 81460889-3191-4450-aee3-bceafc3e621a -->","summary":"","htmlStringContent":"<!-- begin item 5e3fbd96-1689-4cd7-b0b9-b3127658fba1 --><!-- begin field f477dde3-8458-461d-a212-a3322516aecb --><ul><li><strong>For acute gout:</strong><ul><li>Give 500 micrograms of colchicine, two to four times a day, until pain relief is achieved, or diarrhoea or vomiting occurs.<ul><li>Do not exceed a total dose of 6 mg of colchicine (i.e. up to 6 days with colchicine 500 micrograms twice a day, or up to 3 days with colchicine 500 micrograms four times a day), <em>and</em></li><li>Do not repeat treatment within three days.</li></ul></li><li>In the elderly or people with an eGFR of 10-50 mL/minute/1.73m<sup>2</sup> use a reduced dose or increase the dosage interval. Colchicine is contraindicated in people with an eGFR less than 10 mL/minute/1.72m<sup>2</sup>.</li></ul></li><li><strong>For prophylaxis of gout (during urate-lowering treatment):</strong><ul><li>Give 500 micrograms of colchicine once or twice a day following initiation of long-term treatment with allopurinol or febuxostat. For more information, see the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/gout/prescribing-information/allopurinol/#dose\">Allopurinol</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/gout/prescribing-information/febuxostat/#prescribing-febuxostat\">Febuxostat</a>.</li><li>Use colchicine for prophylaxis of gout with caution in people with renal impairment. Limit the dose to:<ul><li>500 micrograms once a day for people with an eGFR of 30-60 mL/minute/1.72m<sup>2</sup>.</li><li>500 micrograms every 2-3 days in people with eGFR 10-30 mL/minute/1.72m<sup>2</sup>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Hui, 2017</a>] </p><!-- end field f477dde3-8458-461d-a212-a3322516aecb --><!-- end item 5e3fbd96-1689-4cd7-b0b9-b3127658fba1 -->","subChapters":[]},{"id":"112b1e67-39fd-5708-bb5d-b0cac51eab66","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 14200a9d-da82-4210-a10e-6395386b9697 --><h3>What are the adverse effects of colchicine?</h3><!-- end field 14200a9d-da82-4210-a10e-6395386b9697 -->","summary":"","htmlStringContent":"<!-- begin item bc6b78be-d18a-4017-99f4-a40b7b040fbe --><!-- begin field c81db676-d312-4035-b65e-7c48f59393b3 --><p><strong>Adverse effects of colchicine include:</strong></p><ul><li>Gastrointestinal — nausea and vomiting, abdominal pain. Common, and can be severe enough to limit treatment.</li><li>Alopecia</li><li>Blood disorders</li><li>Inhibition of spermatogenesis</li><li>Myopathy and peripheral neuritis</li></ul><p>The severity of adverse effects of colchicine is dose-dependent.</p><ul><li>A low-dose regime may produce fewer adverse effects.</li></ul><p>Colchicine has a narrow therapeutic index and is extremely toxic in overdose.</p><ul><li>Refer for medical assessment in overdose even if the person has no symptoms.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Underwood, 2006a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">MHRA, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">BNF 74, 2017</a>]</p><!-- end field c81db676-d312-4035-b65e-7c48f59393b3 --><!-- end item bc6b78be-d18a-4017-99f4-a40b7b040fbe -->","subChapters":[]},{"id":"c30c5f71-8041-5fc0-adfb-b2da847bc17c","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 42296c15-8faa-4fba-bd86-c99087f8cd5d --><h3>Who should avoid taking colchicine?</h3><!-- end field 42296c15-8faa-4fba-bd86-c99087f8cd5d -->","summary":"","htmlStringContent":"<!-- begin item 04b2cbb5-0d91-4fc8-8cee-3a121bb82815 --><!-- begin field 8a1d84a4-27ec-4b49-8513-c3f56d6fccba --><ul><li>Colchicine has a narrow therapeutic index and is extremely toxic in overdose.</li><li>Avoid colchicine in people:<ul><li>With blood disorders.</li><li>With an eGFR less than 10, as colchicine is excreted by the kidneys and, in people with renal impairment, there is the potential for accumulation and toxicity</li><li>Who are pregnant or breastfeeding.<ul><li>In the rare event of a pregnant or breastfeeding woman presenting with gout, colchicine should be avoided and the woman should be referred to a specialist if she requires treatment.</li></ul></li><li>With severe hepatic impairment.</li><li>Taking P-glycoprotein inhibitors, such as clarithromycin, erythromycin, ritonavir and verapamil, or strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.</li></ul></li><li>Ideally, colchicine should also be avoided in:<ul><li>The elderly, who are more prone to dehydration, colchicine is also best avoided because of its relatively high risk of causing diarrhoea.</li><li>People with poor renal function, poor liver function, gastrointestinal disease, or cardiac disease.</li><li>Women of childbearing age unless using effective contraception.</li></ul></li><li>Use caution in people also receiving a statin.</li><li>In overdose, colchicine can cause confusion, reduced cardiac output, cardiac arrhythmias, renal damage, liver damage, respiratory distress, hyperpyrexia, and bone-marrow depression.</li><li>These recommendations regarding colchicine prescribing are based on a guideline produced by the British Society for Rheumatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Hui, 2017</a>], the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">BNF 74, 2017</a>]  the summary of product characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI Medicines Compendium, 2017b</a>] and [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">MHRA, 2009</a>].</li></ul><!-- end field 8a1d84a4-27ec-4b49-8513-c3f56d6fccba --><!-- end item 04b2cbb5-0d91-4fc8-8cee-3a121bb82815 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}